Respiratory Syncytial Virus Infections clinical trials

Explore recruiting respiratory syncytial virus infections clinical trials.

Recruiting respiratory syncytial virus infections studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Respiratory Syncytial Virus Infections trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, open-label, randomized, controlled study to evaluate the immune response, safety and reactogenicity of RSVPreF3 OA investigational vaccine when co-administered with a COVID-19 mRNA vaccine (Omicron XBB.1.5) in adults aged 50 years and above.

Spain, Belgium, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2b, non-randomized, controlled, open-label, extension study to evaluate the persistence of immune response of the adjuvanted RSVPreF3 vaccine and the safety and immunogenicity following revaccination in lung and kidney transplant recipients (≥18 years of age)

Italy, Germany, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase 3, randomized, open-label, multi-country study to evaluate the immunogenicity, safety, reactogenicity and persistence of a single dose of the RSVPreF3 OA investigational vaccine and different revaccination schedules in adults aged 60 years and above.

Finland, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3b, open-label study to evaluate the non-inferiority of the immune response and to evaluate the safety of the RSVPreF3 OA investigational vaccine in adults 18-49 years of age at increased risk of respiratory syncytial virus disease, compared to older adults ≥60 years of age.

Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase 3b, randomized, open label, multi-country, multi-center, extension and crossover vaccination study to evaluate the immunogenicity and safety of different revaccination schedules and persistence of a single dose of the RSVPreF3 OA vaccine in adults aged 60 years and above who participated in the RSV OA=ADJ-006 study

Germany, Finland, Estonia, Belgium, Poland, Spain +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, randomized, controlled, partially blind, immuno-bridging study to evaluate immunogenicity, reactogenicity, safety and the occurrence of RSV-associated respiratory tract illness after administration of a single dose of GSK’s RSVPreF3 OA investigational vaccine in adults aged 60 years and older.

Finland, Poland, Spain

Phase III and phase IV (Integrated) EU CTIS Study details

Respiratory Syncytial Virus Infections trials by city

Respiratory Syncytial Virus Infections in Toronto Respiratory Syncytial Virus Infections in Vancouver Respiratory Syncytial Virus Infections in Montreal Respiratory Syncytial Virus Infections in Calgary Respiratory Syncytial Virus Infections in Edmonton Respiratory Syncytial Virus Infections in Ottawa Respiratory Syncytial Virus Infections in Winnipeg Respiratory Syncytial Virus Infections in Quebec City Respiratory Syncytial Virus Infections in Hamilton Respiratory Syncytial Virus Infections in Kitchener Respiratory Syncytial Virus Infections in London Respiratory Syncytial Virus Infections in Halifax Respiratory Syncytial Virus Infections in New York Respiratory Syncytial Virus Infections in Los Angeles Respiratory Syncytial Virus Infections in Chicago Respiratory Syncytial Virus Infections in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease